Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia.

IF 2.2 3区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Chinese Journal of Integrative Medicine Pub Date : 2024-08-27 DOI:10.1007/s11655-024-3916-0
Fu Wang, Dong-Yue Ma, Jiu-Tian Yang, Dong-Fang Lyu, Qing-He Gao, Chun-Lei Li, Chong-Fu Zhong
{"title":"Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia.","authors":"Fu Wang, Dong-Yue Ma, Jiu-Tian Yang, Dong-Fang Lyu, Qing-He Gao, Chun-Lei Li, Chong-Fu Zhong","doi":"10.1007/s11655-024-3916-0","DOIUrl":null,"url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is one of the most common diseases in elderly men, the incidence of which gradually increases with age and leads to lower urinary tract symptoms (LUTS), which seriously affects the quality of life of patients. Chinese herbal medicines (CHMs) are widely used for the treatment of BPH in China and some other countries. To explore the molecular mechanisms of CHMs for BPH, we conducted a review based on peer-reviewed English-language publications in PubMed and Web of Science databases from inception to December 31, 2023. This article primarily reviewed 32 papers on the use of CHMs and its active compounds in the treatment of BPH, covering animal and cell experiments, and identified relevant mechanisms of action. The results suggest that the mechanisms of action of CHMs in treating BPH may involve the regulation of sex hormones, downregulation of cell growth factors, anti-inflammatory and antioxidative effects, inhibition of cell proliferation, and promotion of apoptosis. CHMs also exhibit α-blocker-like effects, with the potential to relax urethral smooth muscle and alleviate LUTS. Additionally, we also reviewed 4 clinical trials and meta-analyses of CHMs for the treatment of BPH patients, which provided initial evidence of the safety and effectiveness of CHMs treatment. CHMs treatment for BPH shows advantages as a multi-component, multi-target, and multi-pathway therapy, which can mitigate the severity of the disease, improve LUTS, and may become a reliable treatment option in the future.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11655-024-3916-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common diseases in elderly men, the incidence of which gradually increases with age and leads to lower urinary tract symptoms (LUTS), which seriously affects the quality of life of patients. Chinese herbal medicines (CHMs) are widely used for the treatment of BPH in China and some other countries. To explore the molecular mechanisms of CHMs for BPH, we conducted a review based on peer-reviewed English-language publications in PubMed and Web of Science databases from inception to December 31, 2023. This article primarily reviewed 32 papers on the use of CHMs and its active compounds in the treatment of BPH, covering animal and cell experiments, and identified relevant mechanisms of action. The results suggest that the mechanisms of action of CHMs in treating BPH may involve the regulation of sex hormones, downregulation of cell growth factors, anti-inflammatory and antioxidative effects, inhibition of cell proliferation, and promotion of apoptosis. CHMs also exhibit α-blocker-like effects, with the potential to relax urethral smooth muscle and alleviate LUTS. Additionally, we also reviewed 4 clinical trials and meta-analyses of CHMs for the treatment of BPH patients, which provided initial evidence of the safety and effectiveness of CHMs treatment. CHMs treatment for BPH shows advantages as a multi-component, multi-target, and multi-pathway therapy, which can mitigate the severity of the disease, improve LUTS, and may become a reliable treatment option in the future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中药治疗良性前列腺增生症的机制和疗效。
良性前列腺增生(BPH)是老年男性最常见的疾病之一,发病率随年龄增长而逐渐升高,并导致下尿路症状(LUTS),严重影响患者的生活质量。在中国和其他一些国家,中药被广泛用于治疗良性前列腺增生症。为了探索中药治疗良性前列腺增生症的分子机制,我们基于PubMed和Web of Science数据库中从开始到2023年12月31日经同行评审的英文文献进行了综述。本文主要综述了 32 篇关于使用 CHMs 及其活性化合物治疗良性前列腺增生症的论文,涉及动物和细胞实验,并确定了相关的作用机制。结果表明,CHMs 治疗良性前列腺增生症的作用机制可能涉及调节性激素、下调细胞生长因子、抗炎和抗氧化作用、抑制细胞增殖和促进细胞凋亡。CHMs 还具有类似 α 受体阻滞剂的作用,有可能放松尿道平滑肌,缓解尿失禁。此外,我们还回顾了 CHMs 治疗良性前列腺增生症患者的 4 项临床试验和荟萃分析,为 CHMs 治疗的安全性和有效性提供了初步证据。CHMs治疗良性前列腺增生症具有多成分、多靶点、多途径的优势,可减轻疾病的严重程度,改善LUTS,未来可能成为一种可靠的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Chinese Journal of Integrative Medicine
Chinese Journal of Integrative Medicine 医学-全科医学与补充医学
CiteScore
5.90
自引率
3.40%
发文量
2413
审稿时长
3 months
期刊介绍: Chinese Journal of Integrative Medicine seeks to promote international communication and exchange on integrative medicine as well as complementary and alternative medicine (CAM) and provide a rapid forum for the dissemination of scientific articles focusing on the latest developments and trends as well as experiences and achievements on integrative medicine or CAM in clinical practice, scientific research, education and healthcare.
期刊最新文献
Xiangshao Granules Ameliorate Post-Stroke Depression by Inhibiting Activation of Microglia and IDO1 Expression in Hippocampus and Prefrontal Cortex. Therapeutic Role of Chinese Medicine Targeting Nrf2/HO-1 Signaling Pathway in Myocardial Ischemia/Reperfusion Injury. Protective Effect of Silibinin on Lipopolysaccharide-Induced Endotoxemia by Inhibiting Caspase-11-Dependent Cell Pyroptosis. Treg Immunomodulation Contributes to the Anti-atherosclerotic Effects of Huxin Formula in ApoE-/- Mice. Efficacy of Chinese Medicine Treatment Based on Syndrome Differentiation for Primary Insomnia: A Randomized Placebo Controlled Triple-Blinded Trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1